Cbfβ-Expressing Vascular Smooth Muscle Cells for Age-Related Disease Treatment
Summary
The USPTO published patent application US20260097084A1 by Kyungpook National University Industry-Academic Cooperation Foundation covering a pharmaceutical composition containing Cbfβ-expressing vascular smooth muscle cells or culture fluid for preventing or treating age-related diseases. The invention demonstrates that Cbfβ expression in vascular smooth muscle cells inhibits osteoclast differentiation and prevents vascular calcification, offering potential therapeutic applications for conditions such as osteoporosis and age-related vascular disorders.
What changed
The USPTO published patent application US20260097084A1 claiming a pharmaceutical composition comprising Cbfβ-expressing vascular smooth muscle cells or culture fluid as an active ingredient for preventing or treating age-related diseases. The application demonstrates that inhibiting Cbfβ expression promotes vascular calcification and osteoclast differentiation, while culture fluid from Cbfβ-expressing cells inhibits osteoclast differentiation.\n\nPharmaceutical and biotechnology companies developing treatments for age-related diseases, osteoporosis, or vascular calcification conditions should monitor this application's prosecution and evaluate freedom-to-operate implications if their therapeutic approaches involve Cbfβ modulation or vascular smooth muscle cell-based therapies.
What to do next
- Monitor patent prosecution status for potential licensing opportunities
- Assess freedom-to-operate if developing competing vascular or bone therapies
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL COMPOSITION CONTAINING CBFbeta-EXPRESSING VASCULAR SMOOTH MUSCLE CELLS OR CULTURE FLUID THEREOF AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF AGE-RELATED DISEASES
Application US20260097084A1 Kind: A1 Apr 09, 2026
Assignee
KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors
Je-Yong CHOI, Xiangguo CHE, Xian JIN
Abstract
The present invention relates to a pharmaceutical composition containing Cbfβ (Core-binding factor subunit beta) expressing vascular smooth muscle cells or a culture fluid thereof as an active ingredient for the prevention or treatment of age-related diseases. It has been found that inhibition of Cbfβ expression in vascular smooth muscle cells promotes vascular calcification and osteoclast differentiation and that the culture fluid of Cbfβ-expressing vascular smooth muscle cells inhibits osteoclast differentiation. Thus, the composition can be advantageously utilized as a pharmaceutical composition for the prevention, treatment, alleviation, or diagnosis of age-related diseases.
CPC Classifications
A61K 35/44 A61K 38/1709 A61K 45/00 A61P 9/00 A61P 19/10
Filing Date
2023-09-18
Application No.
19114149
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.